The global gene synthesis market size was valued at USD 2.47 billion in 2025 and is projected to grow from USD 2.89 billion in 2026 to USD 10.09 billion by 2034, registering a CAGR of 16.93% during the forecast period from 2026 to 2034. North America dominated the gene synthesis market with a market share of 42.6% in 2025.
Gene synthesis is a synthetic biology technique that produces artificial genes in a lab. It differs from molecular cloning and the polymerase chain reaction because the method relies on solid-phase DNA synthesis (PCR). Gene synthesis is utilized for molecular cloning, producing fusion proteins, or reaching high enough protein expression levels. Compared to conventional molecular cloning methods, the gene synthesis service offers unmatched top-to-bottom customizability while saving time and money.
The chemical in vitro synthesis of double-stranded DNA molecules is known as gene synthesis. It is a tool used in biotechnology and significantly impacts synthetic biology. Gene therapy, vaccine development, molecular engineering, and heterologous gene expression are just a few of the applications of recombinant DNA technology that have emerged as critical tools. It can assist in creating new enzymes for the treatment of cancer and diagnose viral genomes in real-time to develop vaccines. Gene synthesis without a template DNA strand can result in mutated, recombinant, or entirely new DNA sequences. It can also generate DNA sequences, oligos, and RNA with modified bases and chimeric DNA-RNA backbones.
Download a Free Sample To learn more about this report,
Gene Synthesis Is Moving toward More Complex Therapeutic Research
The Gene Synthesis Market is shifting from basic research constructs toward increasingly complex sequences used in synthetic biology and advanced therapeutic research. Demand is being supported by gene and cell therapy programs, where researchers need accurately designed DNA for vector development, screening, analytical testing, and process development. Synthetic gene circuits are also becoming more sophisticated, allowing researchers to study programmable biological functions rather than single genes alone. A 2025 scientific review highlighted applications of synthetic gene circuits in solid tumors, immune regulation, and metabolic diseases, while identifying AI-driven optimization and advanced delivery platforms as important future directions. This expands demand for specialized, high-quality synthesis services.
In October 2025, researchers published a review describing the growing clinical potential of synthetic gene circuits for cell and gene therapies, including applications in cancer and metabolic disease.
Expansion of Cell and Gene Therapies Is Increasing Synthetic DNA Demand
The continued development of cell and gene therapies is a major driver for gene synthesis services. These programs require precisely characterized genetic materials during discovery, vector design, assay development, manufacturing research, and quality testing. As more therapies progress from laboratories toward commercial use, biotechnology companies need dependable suppliers capable of supporting increasingly demanding research and development workflows. Regulatory progress also demonstrates that genetic medicines are moving beyond a small number of early products. In January 2026, the FDA stated that its Center for Biologics Evaluation and Research had approved close to 50 cell and gene therapies over the previous decade, demonstrating the expanding commercial and clinical ecosystem supporting genetic technologies.
In March 2026, the FDA approved Kresladi, the first gene therapy for severe Leukocyte Adhesion Deficiency Type I, adding another rare genetic disease to the commercial gene-therapy landscape.
Biosecurity Compliance Adds Cost and Operational Complexity
Stronger biosecurity requirements can restrain smaller gene synthesis providers because commercial operations increasingly require customer verification, sequence screening, documentation, and compliance processes in addition to manufacturing DNA accurately. Building automated screening infrastructure requires software, trained personnel, databases, security controls, and procedures for handling orders that require additional review. These requirements can raise operating costs and lengthen some transactions, particularly for companies serving research institutions subject to government procurement policies. However, screening is becoming essential for maintaining responsible access to synthetic nucleic acids. The result is a higher compliance barrier for new suppliers and potentially greater competitive advantages for established providers that already operate mature quality, security, and order-review systems.
In May 2025, a U.S. executive order called for synthetic nucleic-acid screening mechanisms to become comprehensive, scalable, and verifiable, with enforcement incorporated into the updated federal framework.
Rare-Disease Therapies Are Expanding High-Value Research Applications
Rare genetic diseases create an important opportunity because many are caused by specific mutations that can increasingly be studied through precisely designed genetic sequences. Synthetic genes can support early research, disease models, analytical standards, vector development, and other controlled development activities for highly targeted therapies. As regulatory agencies create more flexible pathways for treatments addressing small patient populations, biotechnology developers may pursue conditions that previously attracted limited commercial research. This creates opportunities for synthesis companies capable of supplying high-quality research materials with strong documentation and consistency. The opportunity is especially valuable because rare-disease programs often require specialized rather than commodity genetic materials, increasing the importance of technical support and quality assurance.
In April 2026, the FDA approved Otarmeni, the first gene therapy for OTOF-associated genetic hearing loss, only 61 days after its biologics license application was filed.
Therapeutic Safety Requirements Raise the Quality Bar for Genetic Materials
A major challenge is meeting the increasingly demanding quality expectations surrounding genetic medicines. Synthetic DNA used during therapeutic research must support reliable downstream testing, while developers need strong controls over identity, consistency, manufacturing changes, and analytical methods. As therapies become more complex, regulators are also paying closer attention to safety evaluation and manufacturing evidence. The challenge is not limited to obtaining regulatory approval; safety findings can lead to additional monitoring or restrictions after commercialization. Gene synthesis suppliers serving this ecosystem therefore need robust quality systems and consistent materials, while therapy developers must connect genetic design with careful manufacturing and clinical risk assessment throughout development and commercialization.
In April 2026, the FDA issued draft guidance specifically addressing next-generation sequencing approaches for evaluating genome-editing safety, reflecting increasingly detailed expectations for genetic-therapy development.
Chip-based Synthesis is Projected to Register the Fastest Growth at a CAGR of 19.4%
The chip-based synthesis segment is projected to register the fastest growth in the gene synthesis market at a CAGR of 19.4% during the forecast period, driven by increasing demand for high-throughput, scalable, and cost-efficient DNA synthesis technologies. Chip-based platforms enable the simultaneous synthesis of large numbers of oligonucleotide sequences, supporting applications in synthetic biology, genetic engineering, drug discovery, and functional genomics. Advances in microarray technologies, automation, and DNA assembly methods, along with increasing demand for customized genetic sequences, continue to strengthen segment growth.
Request Customizationto receive a tailored report.
Viral DNA Synthesis is Projected to Register the Fastest Growth at a CAGR of 19.1%
The viral DNA synthesis segment is projected to register the fastest growth in the gene synthesis market at a CAGR of 19.1% during the forecast period, supported by increasing demand for synthetic viral sequences in vaccine research, gene therapy, virology studies, and diagnostic development. Viral DNA synthesis enables researchers to obtain customized genetic constructs without relying entirely on naturally isolated viral material. Growing investments in gene-based therapeutics, expanding vaccine development programs, and increasing utilization of viral vectors for advanced therapies continue to drive demand for viral DNA synthesis services.
Gene and Cell Therapy Development Dominated the Market with 39.8% Share in 2025
The gene and cell therapy development segment accounted for the largest share of the global gene synthesis market at 39.8% in 2025, driven by extensive utilization of synthetic genes in therapeutic vector construction, genetic modification, target validation, and development of advanced cell-based treatments. Gene synthesis allows researchers to design and optimize specific DNA sequences required for therapeutic research and manufacturing. Increasing development of gene and cell therapies, growing biotechnology investment, and advancements in genetic engineering and synthetic biology continue to reinforce the segment's dominant market position.
Contract Research Organizations is Projected to Register the Fastest Growth at a CAGR of 19.6%
The contract research organizations segment is projected to register the fastest growth in the gene synthesis market at a CAGR of 19.6% during the forecast period, driven by increasing outsourcing of genetic research, drug discovery, preclinical development, and specialized biotechnology services. CROs provide pharmaceutical and biotechnology companies with access to advanced gene synthesis capabilities, technical expertise, and scalable research infrastructure while helping reduce internal development requirements. Increasing complexity of biotechnology research, growing demand for customized genetic constructs, and rising outsourcing of life sciences R&D activities continue to support segment growth.
Speak to an Analystto discuss market opportunities.
North America dominated the gene synthesis market with the largest 42.6% market share in 2025, representing a market value of USD 1.05 billion. The region is projected to grow at a CAGR of 16.9% during the forecast period. Its leadership is supported by a well-established biotechnology and pharmaceutical industry, extensive genomic research, strong academic infrastructure, and increasing investment in synthetic biology. Gene synthesis services are increasingly used in drug discovery, vaccine development, gene and cell therapy research, molecular diagnostics, protein engineering, and genetic engineering. Improvements in DNA synthesis technologies are helping researchers obtain customized genetic sequences more efficiently. Continued biotechnology investment and expanding synthetic biology applications strengthen North America's position in the global gene synthesis market.
The United States is an important contributor to the gene synthesis market due to its extensive biotechnology ecosystem, major pharmaceutical industry, advanced research institutions, and significant investment in genomics and synthetic biology. Researchers increasingly use customized DNA sequences for gene editing, recombinant protein development, therapeutic research, vaccine development, and molecular biology applications. Growing activity in cell and gene therapies is creating additional requirements for accurate and scalable synthetic DNA solutions. Biotechnology companies are also using gene synthesis to accelerate experimentation and optimize biological constructs. Continued investment in life sciences research, development of automated synthesis technologies, and expansion of biotechnology companies support development of the country's gene synthesis market.
Canada contributes to the gene synthesis market through its growing biotechnology sector, academic research institutions, genomics programs, and expanding life sciences ecosystem. Researchers use synthesized genes across molecular biology, protein engineering, genetic research, diagnostics, and therapeutic development applications. Increasing collaboration between universities, biotechnology companies, healthcare institutions, and research organizations is supporting adoption of advanced genetic technologies. Development of synthetic biology capabilities is also creating opportunities for applications extending beyond healthcare into agriculture and industrial biotechnology. Improvements in DNA synthesis speed, accuracy, and accessibility are further supporting research activity. Continued investment in genomics and biotechnology supports long-term development of Canada's gene synthesis market.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific is the fastest-growing region in the gene synthesis market and is expected to expand at a CAGR of 20.6% during the forecast period. The region accounted for 22.8% of the global market in 2025, representing a market value of USD 0.56 billion. Growth is supported by expanding biotechnology industries, increasing genomic research, rising pharmaceutical R&D expenditure, and growing adoption of synthetic biology technologies. Governments and research institutions are strengthening genomics and precision medicine capabilities, creating demand for customized genetic materials. Expansion of contract research and biopharmaceutical manufacturing is also supporting gene synthesis applications. Increasing availability of advanced laboratory infrastructure and skilled researchers supports strong expansion of the gene synthesis market across Asia Pacific.
Japan is an important contributor to the gene synthesis market through its advanced pharmaceutical industry, sophisticated research infrastructure, strong biotechnology capabilities, and increasing focus on regenerative medicine and genomic technologies. Gene synthesis supports research involving therapeutic proteins, antibodies, vaccines, genetic engineering, cell therapies, and molecular diagnostics. Academic and commercial laboratories increasingly require customized DNA constructs for complex biological experiments and product development. Japan's expertise in precision medicine and regenerative technologies is also broadening potential applications for synthetic genes. Continued research into advanced therapeutics, automation of laboratory processes, and development of synthetic biology technologies strengthen Japan's contribution to the Asia Pacific gene synthesis market.
China plays a significant role in the gene synthesis market due to its rapidly expanding biotechnology industry, substantial pharmaceutical manufacturing base, growing genomics capabilities, and increasing investment in life sciences research. Universities, research institutes, and biotechnology companies utilize synthetic genes for drug discovery, genetic engineering, protein expression, diagnostics, and therapeutic development. Expansion of biopharmaceutical R&D and contract research activities is creating additional demand for customized DNA sequences. Domestic companies are also strengthening capabilities in automated DNA synthesis and synthetic biology. Continued investment in biotechnology infrastructure, genomic research, and advanced therapeutic development reinforces China's importance within the Asia Pacific gene synthesis market.
Europe accounted for 27.4% of the global gene synthesis market in 2025, reaching a market value of USD 0.68 billion. The region is anticipated to grow at a CAGR of 17.2% during the forecast period. Market development is supported by established pharmaceutical and biotechnology industries, strong academic research, increasing synthetic biology activity, and continued investment in genomics and personalized medicine. Researchers use gene synthesis for genetic engineering, drug development, protein production, molecular diagnostics, and advanced therapeutic research. Increasing adoption of automated laboratory technologies is improving research efficiency and supporting broader use of synthetic DNA. Continued development of biotechnology clusters and life sciences research supports expansion of the gene synthesis market across Europe.
Germany is an important contributor to the gene synthesis market in Europe due to its established pharmaceutical industry, strong biotechnology sector, advanced research institutions, and significant expertise in molecular biology. Academic and commercial laboratories utilize synthetic genes for protein engineering, drug discovery, genetic research, diagnostics, and biopharmaceutical development. Increasing research into cell and gene therapies is creating requirements for precise and reliable genetic constructs. Germany's sophisticated life sciences infrastructure also supports collaboration among universities, biotechnology companies, pharmaceutical manufacturers, and research organizations. Continued investment in biotechnology innovation, genomic technologies, and advanced therapeutic research strengthens Germany's position within the European gene synthesis market.
The United Kingdom contributes significantly to the gene synthesis market through its strong genomics ecosystem, pharmaceutical and biotechnology industries, academic research institutions, and expanding synthetic biology capabilities. Researchers increasingly use synthesized DNA for gene editing, therapeutic development, protein engineering, vaccine research, and molecular diagnostics. The country's established genomics research infrastructure supports development of precision medicine and advanced biological technologies. Growing biotechnology entrepreneurship is also increasing demand for outsourced and customized gene synthesis services. Collaboration between universities, healthcare institutions, research organizations, and biotechnology companies supports commercialization of emerging applications. Continued investment in genomic research and synthetic biology supports the United Kingdom's contribution to the European gene synthesis market.
Latin America represented 4.2% of the global gene synthesis market in 2025, with a market value of USD 0.1 billion. The region is expected to register a CAGR of 15.8% during the forecast period. Growth is supported by increasing biotechnology research, development of genomic capabilities, expanding pharmaceutical activities, and growing academic interest in molecular biology and synthetic biology. Research institutions are increasingly adopting advanced genetic tools for healthcare, agriculture, infectious disease research, and biological sciences. Improvements in laboratory infrastructure and greater availability of commercial gene synthesis services are supporting wider adoption. Growing collaboration between universities and biotechnology organizations further supports continued expansion of the gene synthesis market across Latin America.
Brazil is an important contributor to the gene synthesis market in Latin America due to its established biomedical research institutions, growing biotechnology sector, agricultural biotechnology activities, and expanding genomic research capabilities. Researchers use synthetic DNA in molecular biology, infectious disease research, protein engineering, genetic modification, diagnostics, and agricultural applications. The country's large agricultural industry also creates opportunities for synthetic biology technologies related to crop improvement and biological products. Increasing collaboration among universities, research centers, biotechnology companies, and pharmaceutical organizations is strengthening demand for advanced genetic technologies. Continued development of laboratory infrastructure and biotechnology expertise reinforces Brazil's importance within the regional gene synthesis market.
The Middle East and Africa accounted for 3% of the global gene synthesis market in 2025, representing a market value of USD 0.07 billion. The region is projected to expand at a CAGR of 14.9% during the forecast period. Market development is supported by growing investment in biotechnology, genomics, healthcare research, and advanced laboratory infrastructure. Research institutions are increasingly exploring synthetic DNA technologies for genetic research, diagnostics, precision medicine, and infectious disease studies. Expansion of academic and healthcare research capabilities is improving access to sophisticated molecular biology technologies. International research collaborations and development of biotechnology ecosystems are creating additional opportunities. These factors support long-term development of the gene synthesis market across the region.
The UAE contributes to the gene synthesis market within the Middle East and Africa through its growing investment in genomics, precision medicine, biotechnology, and advanced healthcare research. Research institutions and biotechnology organizations can utilize synthesized genetic material for molecular diagnostics, genetic studies, therapeutic research, and biological engineering applications. Development of advanced laboratory infrastructure and increasing emphasis on genomic medicine are creating opportunities for specialized gene synthesis services. Collaboration with international research organizations is also helping expand access to sophisticated biotechnology expertise and technologies. Continued investment in life sciences, genomic research, and healthcare innovation strengthens the UAE's role in the regional gene synthesis market.
The gene synthesis market is highly competitive, with major companies such as GenScript Biotech, Thermo Fisher Scientific, Integrated DNA Technologies (IDT), Twist Bioscience, Eurofins Genomics, GENEWIZ (Azenta Life Sciences), OriGene Technologies, Boster Biological Technology, ProteoGenix, and ProMab Biotechnologies competing through advanced synthesis platforms, high-throughput automation, and customized DNA services. Leading companies are increasingly focusing on faster turnaround times, complex and long DNA sequences, scalable synthesis, AI-enabled drug discovery, and integrated gene-to-protein workflows. Technological differentiation is also being driven by chip-based synthesis, automation, improved sequence accuracy, and cost-efficient manufacturing. GenScript, Thermo Fisher Scientific, Twist Bioscience, IDT, and Eurofins are among the prominent participants in the competitive landscape.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Mass Spectrometry Market Size, Share, Growth, Analysis, 2034
Blood Testing Market Size, Share, Growth, Analysis, Report, 2034
3D Cell Culture Market Size, Share, Growth, Analysis, Report, 2034
3D Bioprinting Market Size, Share, Growth, Analysis, Report, 2034
United Kingdom Epigenetics Market Size, Trends, Top Share and Forecast to 2034
Bovine Serum Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com